8-K: Myriad Genetics Discontinues Part Two of Economic Utility Study Due to Control Group Disparities

Myriad Genetics has halted the second part of its economic utility study on GeneSight testing due to significant disparities found in the control group, rendering the comparison unreliable.

Summary

• Myriad Genetics previously reported initial results from a study linking GeneSight testing to insurance claims data.
• Part one of the study showed a 29% decrease in hospitalizations for any reason and a 39% decrease in psychiatric-related hospitalizations within 180 days of GeneSight testing.
• The company hypothesized that GeneSight testing contributed to these reductions, but part one lacked a control group.
• Part two of the study aimed to compare hospital resource utilization and costs between patients who received GeneSight testing and a matched control group.
• Significant disparities were found in baseline hospital resource utilization and costs between the GeneSight group and the identified control group.
• Myriad Genetics concluded that the control group was not viable, making any comparison unreliable.
• As a result, the company has discontinued the analysis for part two of the study.

Sentiment

Score: 4

Explanation: The discontinuation of part two of the study is a negative development, indicating a setback in validating the economic benefits of GeneSight testing. However, the company's transparency in disclosing the issue is a positive.

Positives

• Part one of the study showed a significant reduction in hospitalizations associated with GeneSight testing.

Negatives

• Part two of the study was discontinued due to an unsuitable control group.
• The company was unable to validate the hypothesis that GeneSight testing was the cause of the reduction in hospitalizations.

Risks

• The inability to complete part two of the study may hinder the company's ability to demonstrate the economic benefits of GeneSight testing.
• The lack of a viable control group raises questions about the validity of the initial findings from part one of the study.

Future Outlook

The company plans to publish the full results of part one of the study in the near future.

Industry Context

This announcement highlights the challenges in conducting retrospective studies using real-world data, particularly in identifying suitable control groups. It underscores the importance of robust study design and data quality in healthcare research.

Comparison to Industry Standards

• Retrospective studies using insurance claims data are common in healthcare research, but the challenge of finding well-matched control groups is a known issue.
• Other companies conducting similar studies often face similar challenges in data quality and control group selection.
• The decision to discontinue the study due to control group disparities is a responsible approach, aligning with best practices in research methodology.

Stakeholder Impact

• Shareholders may react negatively to the news of the discontinued study.
• The inability to validate the economic benefits of GeneSight testing may impact the company's ability to market the product effectively.
• Healthcare providers may have less confidence in the economic value of GeneSight testing.

Next Steps

• The company plans to publish the full results of part one of the study in the near future.

Key Dates

Keywords

GeneSight, Myriad Genetics, economic utility study, hospitalization, psychiatric, control group, healthcare, insurance claims, testing